A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

StatusWithdrawn
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Withdrawn Sponsor's reason: sponsor closed study Show 4 more changesShow less
    • Enrollment target: estimated 14 to confirmed 0
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 65 words
    • Site details revised at 10 of 10 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
Trial Details
NCT Number NCT07428044
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
Related terms Carcinoma, Non-Small-Cell Lung
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov